

Overview table. Uncertainty #8= immunotherapy

Intervention	Review information						Number search records (date)	N (potential new studies)	Action
	Review ID	Review status	Date of last search	Number of studies	Number of participants	Outcomes (listed in SOF table)			
Anti-IL5 therapies for asthma (Mepolizumab, reslizumab, benralizumab)	MEP-AST	Published 2017	29 March 2017	13	6000	Rate of exacerbations requiring systemic corticosteroids; Rate of exacerbations requiring emergency department treatment or admission; HRQoL (ACQ); HRQoL (SGRQ); prebronchodilator FEV1; AEs leading to discontinuation		6 ongoing studies in 2017 version.	Update when new studies published.
Anti-interleukin-13 and anti-interleukin-4 agents versus placebo, anti-interleukin-5 or	AL13-AST	Protocol published, review in development	19 January 2019	tbc	tbc	tbc	-	-	Complete/publish review

anti-immunoglobulin-E agents, for children and adults with asthma									
<p>Omalizumab for asthma in adults and children</p> <p>Omalizumab (IV, sub-cutaneous, inhaled) vs placebo</p>	IGE-AST	Published 2013	13 June 2013	25	6382	Number of participants with at least one exacerbation (all, moderate, severe asthma reported separately); mortality; hospitalisations; SAEs	<p>Date of search: 17 october 2018</p> <p>140 records from Cochrane Airways Register of Trials</p>	<p>6 ongoing studies published since last published update;</p> <p>2 ongoing studies with status unknown.</p>	Update and change title to include placebo